Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- PennyStockEarnings Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is On: Keryx Biopharmaceuticals (NASDAQ:KERX), DaVita HealthCare Partners Inc (NYSE:DVA), Galena Biopharma Inc (NASDAQ:GALE), Quest Diagnostics Inc (NYSE:DGX)
Keryx Biopharmaceuticals (NASDAQ:KERX) slipped -1.94% and closed at $9.59 in the last trading session with the overall traded volume of 3.13 million shares, more versus the average volume of 1.46 million shares. Its 52 weeks high price was $10.03 and suffered lowest price of $2.23 in the same period.
It has market cap of $784.61 million while its total outstanding shares are 81.82 million. Its stock’s 3 months performance stands at +21.39%. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States.
Will KERX Get Buyers Even After The Recent Rally? Find Out Here
DaVita HealthCare Partners Inc (NYSE:DVA) declined -0.10% with the closing price of $58.47. The overall volume in the last trading session was 2.83 million shares. Its fifty two week range was $48.80-$65.67. The total market capitalization remained $12.43 billion.
The stock gained +6.54% in this year and reported the increase of +4.88% in the last 5 days. In its share capital, the company has 212.60 billion outstanding shares. DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States.
Has DVA Found The Bottom And Ready To Gain Momentum? Find Out Here
Galena Biopharma Inc (NASDAQ:GALE) increased +0.51% to close at $1.99 in the last trading session and its total traded volume was 2.85 million shares, beating the average volume of 2.47 million. The company has market cap of $168.02 million.
The stock has positive year-to-date performance of +32.67% while its quarterly performance remained +2.58%. Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care.
Will GALE Continue To Move Higher? Find Out Here
Quest Diagnostics Inc (NYSE:DGX) moved up +0.31% to closed at $62.00 and its overall volume in the last trading session was 2.74 million shares, beating the average volume of 1.14 million. It has market cap of $9.42 billion while its total outstanding shares are 151.89 million.
The stock gained +7.42% in this year and reported the increase of +0.93% in the last 5 days. Its 3 months performance stands at +1.96%. Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions.
Why Should Investors Buy DGX After The Recent Gain? Just Go Here and Find Out
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)